Radiation Oncology Journal

  • 제37권3호
  • /
  • Pages.176-184
  • /
  • 2019
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Chemoradiotherapy versus radiotherapy alone following induction chemotherapy for elderly patients with stage III lung cancer

  • Kim, Dong-Yun (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Song, Changhoon (Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Se Hyun (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Yu Jung (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Lee, Jong Seok (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Jae-Sung (Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • 투고 : 2019.02.07
  • 심사 : 2019.06.24
  • 발행 : 2019.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: It is unclear whether adding concurrent chemotherapy (CT) to definitive radiotherapy (RT) following induction CT is a tolerable and cost effective treatment for non-small-cell lung cancer (NSCLC) patients aged 70 years or older with comorbidities. This study evaluated the actual clinical outcomes between concurrent chemoradiotherapy (CCRT) and RT alone following induction CT or not in patients (≥70 years) in a single institution's clinical practice. Materials and Methods: A total of 82 patients with unresectable stage III NSCLC between 2004 and 2016 were retrospectively analyzed. Their treatment tolerance and clinical outcomes such as overall survival (OS), locoregional recurrence (LRR), treatment toxicities and distant metastasis (DM) were evaluated. Early mortality rates were also evaluated as 4-month mortality after RT. Results: Fifty-four patients received CCRT and 28 patients received RT alone. Induction CT before RT was performed for 68.5% and 50.0% in CCRT and RT alone groups. Treatment tolerance was significantly worse in CCRT (p = 0.046). The median survival was 21.1 and 18.1 months for CCRT and RT alone, which was not statistically significant. LRR and DM were also not different. Most early deaths after CCRT were attributed to non-cancer-related mortality. Acute esophagitis of grade ≥2 occurred more following CCRT (p = 0.017). In multivariate analysis, a Charlson Comorbidity Index (CCI) of ≥5 and a weight loss of ≥5% after RT were associated with poor OS. The factors adversely affecting 4-month survival were a CCI of ≥5 and CCRT. Conclusion: There were no significant differences in OS, LRR, and DM between CCRT and RT alone treatment in elderly patients. However, there was a poorer tolerance and higher incidence of acute esophagitis in the CCRT group. Specifically, when the patients had a CCI of ≥5, RT alone seems to be reasonable with a low probability of early death.

키워드

참고문헌

  1. Driessen EJ, Bootsma GP, Hendriks LE, et al. Stage III Non- Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. Radiother Oncol 2016;121:26-31. https://doi.org/10.1016/j.radonc.2016.07.025
  2. Sacher AG, Le LW, Leighl NB, Coate LE. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol 2013;8:366-8. https://doi.org/10.1097/JTO.0b013e31827e2145
  3. Atagi S, Mizusawa J, Ishikura S, et al. Randomized trial of thoracic radiotherapy with or without concurrent daily lowdose carboplatin in elderly patients with locally advanced non-small cell lung cancer (NSCLC): long-term follow-up of Japan Clinical Oncology Group (JCOG) study JCOG0301. J Clin Oncol 2017:35(15_Suppl):8532. https://doi.org/10.1200/JCO.2017.35.15_suppl.8532
  4. Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012;13:671-8. https://doi.org/10.1016/S1470-2045(12)70139-0
  5. Dawe DE, Christiansen D, Swaminath A, et al. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2016;99:180-5. https://doi.org/10.1016/j.lungcan.2016.07.016
  6. Miller ED, Fisher JL, Haglund KE, et al. The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer. J Thorac Oncol 2018;13:426-35. https://doi.org/10.1016/j.jtho.2017.11.135
  7. Driessen EJ, Schulkes KJ, Dingemans AC, van Loon JG, Hamaker ME, Aarts MJ, et al. Patterns of treatment and survival among older patients with stage III non-small cell lung cancer. Lung Cancer 2018;116:55-61. https://doi.org/10.1016/j.lungcan.2017.12.013
  8. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57):1288-94.
  9. Ezer N, Smith CB, Galsky MD, et al. Cisplatin vs. carboplatinbased chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer. Radiother Oncol 2014;112:272-8. https://doi.org/10.1016/j.radonc.2014.07.014
  10. Harris JP, Murphy JD, Hanlon AL, Le QT, Loo BW Jr, Diehn M. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;88:872-84. https://doi.org/10.1016/j.ijrobp.2013.12.010
  11. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90. https://doi.org/10.1200/JCO.2009.26.2543
  12. Fournel P, Vergnenegre A, Robinet G, et al. Induction or consolidation chemotherapy for unresectable stage III nonsmall-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC-IFCT 02-01. Eur J Cancer 2016;52:181-7. https://doi.org/10.1016/j.ejca.2015.10.072
  13. Holgersson G, Sandelin M, Hoye E, et al. The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy. Anticancer Res 2012;32:1339-46.
  14. Ardizzzoni A, Boni L, Scolaro T, et al. Induction chemotherapy followed by thoracic irradiation with or without concurrent chemotherapy in locally advanced inoperable NSCLC: a randomized phase III trial. J Clin Oncol 2008:26(15_ Suppl):7520. https://doi.org/10.1200/jco.2008.26.15_suppl.7520
  15. Huang EH, Liao Z, Cox JD, et al. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 2007;68:779-85. https://doi.org/10.1016/j.ijrobp.2007.01.002
  16. Luo H, Yu X, Liang N, Xie J, Deng G, Liu Q, Zhang J, Zhang J, Ge H. The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6165. https://doi.org/10.1097/md.0000000000006165
  17. Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol 2018;19:e305-e316. https://doi.org/10.1016/S1470-2045(18)30348-6

피인용 문헌

  1. Nutritional Support in Lung Cancer Patients: The State of the Art vol.22, pp.4, 2021, https://doi.org/10.1016/j.cllc.2020.10.008